In this regard, there is a need for further investigations to clarify the precise molecular mechanisms of these SNPs, particularly SIRT5 rs12216101, which might pave the way for the development of new therapy in patients with MASLD. This evidence concerns the gene SIRT5 and metabolic dysfunction-associated steatotic liver disease.